We provide recommendations for use of specific obesity pharmacotherapies with proven benefit in specific subpopulations atherosclerotic cardiovascular disease, heart failure with preserved ejection fraction, metabolic dysfunctionassociated steatohepatitis, prediabetes, type 2 diabetes, obstructive sleep apnea, osteoarthritis and for those with certain specific monogenic causes of obesity
MOTS-c + CJC-1295/Ipamorelin: For patients pursuing both metabolic optimization and growth hormone support
John Salerno for a GLP-1 Therapy Consultation in Manhattan NY and Connecticut If you are struggling with type 2 diabetes or seeking effective weight management solutions, exploring GLP-1 therapy with Dr
PubMed record Staresinic M, et al
Pierre, here are six health conditions that weight loss drugs may help with: Diabetes: GLP-1 agonists were originally developed as diabetes medications